Silverfin false false 31/12/2025 01/01/2025 31/12/2025 Mr R B Gray 21/01/2007 Mrs C M Gurney 01/02/2012 Dr R P D Hancock 04/01/2007 Mr J M Oates 27/01/2012 Mr T E Skwarek 27/01/2012 31 July 2026 no description of principal activity 06041277 2025-12-31 06041277 bus:Director1 2025-12-31 06041277 bus:Director2 2025-12-31 06041277 bus:Director3 2025-12-31 06041277 bus:Director4 2025-12-31 06041277 bus:Director5 2025-12-31 06041277 2024-12-31 06041277 core:CurrentFinancialInstruments 2025-12-31 06041277 core:CurrentFinancialInstruments 2024-12-31 06041277 core:Non-currentFinancialInstruments 2025-12-31 06041277 core:Non-currentFinancialInstruments 2024-12-31 06041277 core:ShareCapital 2025-12-31 06041277 core:ShareCapital 2024-12-31 06041277 core:CapitalRedemptionReserve 2025-12-31 06041277 core:CapitalRedemptionReserve 2024-12-31 06041277 core:RetainedEarningsAccumulatedLosses 2025-12-31 06041277 core:RetainedEarningsAccumulatedLosses 2024-12-31 06041277 core:OfficeEquipment 2024-12-31 06041277 core:OfficeEquipment 2025-12-31 06041277 core:CostValuation 2024-12-31 06041277 core:CostValuation 2025-12-31 06041277 2025-01-01 2025-12-31 06041277 bus:FilletedAccounts 2025-01-01 2025-12-31 06041277 bus:SmallEntities 2025-01-01 2025-12-31 06041277 bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 06041277 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 06041277 bus:Director1 2025-01-01 2025-12-31 06041277 bus:Director2 2025-01-01 2025-12-31 06041277 bus:Director3 2025-01-01 2025-12-31 06041277 bus:Director4 2025-01-01 2025-12-31 06041277 bus:Director5 2025-01-01 2025-12-31 06041277 core:OfficeEquipment core:TopRangeValue 2025-01-01 2025-12-31 06041277 2024-01-01 2024-12-31 06041277 core:OfficeEquipment 2025-01-01 2025-12-31 iso4217:GBP xbrli:pure

Company No: 06041277 (England and Wales)

# PROSPEKT MEDICAL LIMITED

### Unaudited Financial Statements
For the financial year ended 31 December 2025
Pages for filing with the registrar

PROSPEKT MEDICAL LIMITED

## Unaudited Financial Statements

For the financial year ended 31 December 2025

Contents

PROSPEKT MEDICAL LIMITED

## COMPANY INFORMATION

For the financial year ended 31 December 2025
PROSPEKT MEDICAL LIMITED

## COMPANY INFORMATION (continued)

For the financial year ended 31 December 2025

DIRECTORS | Mr R B Gray
| Mrs C M Gurney
| Dr R P D Hancock
| Mr J M Oates
| Mr T E Skwarek

SECRETARY | Mr R B Gray

REGISTERED OFFICE | 9 St. Simon's Avenue
| London
| SW15 6DU
| United Kingdom

COMPANY NUMBER | 06041277 (England and Wales)

PROSPEKT MEDICAL LIMITED

## BALANCE SHEET

As at 31 December 2025
PROSPEKT MEDICAL LIMITED

## BALANCE SHEET (continued)

As at 31 December 2025

| Note | 2025 |  | 2024
|  | £ |  | £
Fixed assets |  |  |  |
Tangible assets | 3 | 177 |  | 0
Investments | 4 | 1,542,459 |  | 1,542,459
|  | 1,542,636 |  | 1,542,459
Current assets |  |  |  |
Debtors |  |  |  |
- due within one year | 5 | 50,482 |  | 0
- due after more than one year | 5 | 96,865 |  | 143,925
Cash at bank and in hand |  | 18,966 |  | 21,162
|  | 166,313 |  | 165,087
Prepayments and accrued income |  | 80,026 |  | 222,273
Creditors: amounts falling due within one year | 6 | ( 715,629) |  | ( 775,530)
Net current liabilities |  | (469,290) |  | (388,170)
Total assets less current liabilities |  | 1,073,346 |  | 1,154,289
Net assets |  | 1,073,346 |  | 1,154,289
Capital and reserves |  |  |  |
Called-up share capital |  | 92,136 |  | 92,136
Capital redemption reserve |  | 14,164 |  | 14,164
Profit and loss account |  | 967,046 |  | 1,047,989
Total shareholders' funds |  | 1,073,346 |  | 1,154,289

For the financial year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
- These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Profit and Loss Account has not been delivered.

The financial statements of Prospekt Medical Limited (registered number: 06041277) were approved and authorised for issue by the Board of Directors on 31 July 2026. They were signed on its behalf by:

Mr R B Gray Director |

PROSPEKT MEDICAL LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2025
PROSPEKT MEDICAL LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2025

##### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

##### General information and basis of accounting

Prospekt Medical Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 9 St. Simon's Avenue, London, SW15 6DU, England, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the company and rounded to the nearest £.

##### Going concern

The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors note that the business has net assets of £1,073,346. The company is supported through loans from the directors. The directors have confirmed that the loan facilities will continue to be available for at least 12 months from the date of signing these financial statements and the directors will continue to support the company. Given the current position, the directors believe that any foreseeable debts can be met for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

##### Group accounts exemption

Group accounts exemption s399
As the company is subject to the small companies regime, group accounts have not been prepared.

##### Foreign currency

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing on the initial transaction dates. Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

##### Turnover

Turnover comprises income for the provision of services in the ordinary course of the company's activities. Turnover is shown net of sales/ value added tax. The company recognises turnover when the services have been supplied to the customer.

##### Taxation

Current tax
The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.
Deferred tax
Deferred tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company.
Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.
The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

##### Tangible fixed assets

Tangible assets are held under the cost model

Office equipment | 5 years straight line

Tangible assets are depreciated on a straight line basis for their respective useful economic life.

##### Fixed asset investments

The investments in subsidiaries are measured at cost less impairment.

##### Financial instruments

Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments.

##### Ordinary share capital

Ordinary shares are classified as equity.

##### Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due.
If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

#### 2. Employees

| 2025 |  | 2024
| Number |  | Number
Monthly average number of persons employed by the company during the year, including directors | 2 |  | 2

#### 3. Tangible assets

| Office equipment |  | Total
| £ |  | £
Cost |  |  |
At 01 January 2025 | 9,750 |  | 9,750
Additions | 190 |  | 190
At 31 December 2025 | 9,940 |  | 9,940
Accumulated depreciation |  |  |
At 01 January 2025 | 9,750 |  | 9,750
Charge for the financial year | 13 |  | 13
At 31 December 2025 | 9,763 |  | 9,763
Net book value |  |  |
At 31 December 2025 | 177 |  | 177
At 31 December 2024 | 0 |  | 0

#### 4. Fixed asset investments

Investments in subsidiaries

| 2025
| £
Cost |
At 01 January 2025 | 1,542,459
At 31 December 2025 | 1,542,459
Carrying value at 31 December 2025 | 1,542,459
Carrying value at 31 December 2024 | 1,542,459

Investments in group undertakings represents a 100% interest in Prospekt Medical Caspian LLP, a partnership incorporated in Kazakhstan and an 80% interest in German Industrial and Medical Consulting, a company incorporated in Azerbaijan.

#### 5. Debtors

| 2025 |  | 2024
| £ |  | £
Debtors: amounts falling due within one year |  |  |
Corporation tax | 23,842 |  | 0
Other debtors | 26,640 |  | 0
| 50,482 |  | 0
Debtors: amounts falling due after more than one year |  |  |
Amounts owed by group undertakings (note 7) | 96,865 |  | 143,925

#### 6. Creditors: amounts falling due within one year

| 2025 |  | 2024
| £ |  | £
Amounts owed to group undertakings (note 7) | 357,429 |  | 383,733
Amounts owed to directors (note 7) | 339,320 |  | 294,320
Accruals | 12,376 |  | 67,730
Taxation and social security | 44 |  | 23,830
Other creditors | 6,460 |  | 5,917
| 715,629 |  | 775,530

#### 7. Related party transactions

During the year, the Director's loan increased by £45,000 (2024 - £120,000). At the balance sheet date, the amount due to the Director was £339,320 (2024 - £294,320). The Director's loan is interest free and repayable on demand.
At the balance sheet date, the amount owed to the company by German Industrial and Medical Consulting was £96,865 (2024 - £143,925).
The exemption is taken under FRS 102 paragraph 1AC.35 not to disclose transactions with other undertakings wholly owned within the group.